Michelle N Rheault

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8375360/publications.pdf

Version: 2024-02-01

66 papers 2,068 citations

236925 25 h-index 243625 44 g-index

67 all docs

67 docs citations

67 times ranked

2884 citing authors

#	Article	IF	CITATIONS
1	Multisite Retrospective Review of Outcomes in Renal Replacement Therapy for Neonates with Inborn Errors of Metabolism. Journal of Pediatrics, 2022, 246, 116-122.e1.	1.8	4
2	Utility of the 2018 revised ISN/RPS thresholds for glomerular crescents in childhood-onset lupus nephritis: a Pediatric Nephrology Research Consortium study. Pediatric Nephrology, 2022, 37, 3139-3145.	1.7	3
3	Cardiovascular disease in children with chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 231-236.	2.0	8
4	Genetic Basis of Type IV Collagen Disorders of the Kidney. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1101-1109.	4.5	29
5	lgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine. Kidney International, 2021, 100, 705-706.	5.2	58
6	Liver transplant as a curative treatment in a pediatric patient with classic homocystinuria: A case report. American Journal of Medical Genetics, Part A, 2021, 185, 1247-1250.	1.2	4
7	Optimizing the Electronic Health Record for Clinical Research: Has the Time Come?. Kidney360, 2021, 2, 1880-1881.	2.1	O
8	The importance of clinician, patient and researcher collaborations in Alport syndrome. Pediatric Nephrology, 2020, 35, 733-742.	1.7	15
9	Role of direct oral anticoagulants in patients withÂkidney disease. Kidney International, 2020, 97, 664-675.	5.2	35
10	Approach to Persistent Microscopic Hematuria in Children. Kidney360, 2020, 1, 1014-1020.	2.1	4
11	Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?. Kidney International, 2020, 98, 1400-1402.	5.2	2
12	Renal Survival in Children with Glomerulonephritis with Crescents: A Pediatric Nephrology Research Consortium Cohort Study. Journal of Clinical Medicine, 2020, 9, 2385.	2.4	12
13	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. Kidney International Reports, 2020, 5, 860-871.	0.8	2
14	Segmental infantile hemangioma and concomitant hypertension in three African American neonates. Pediatric Dermatology, 2020, 37, 524-526.	0.9	2
15	Glomerular disease in children: when to biopsy. Nephrology Dialysis Transplantation, 2020, 36, 1803-1805.	0.7	1
16	A dual efficacy-implementation trial of a novel mobile application for childhood nephrotic syndrome management: the UrApp for childhood nephrotic syndrome management pilot study protocol (UrApp) Tj ETQq0	0 0.18 gBT /	'Ov e rlock 10 T
17	Clinical trial recommendations for potential Alport syndrome therapies. Kidney International, 2020, 97, 1109-1116.	5.2	7
18	Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 714-716.	4.5	74

#	Article	IF	CITATIONS
19	Developing Consensus-Based Outcome Domains for Trials in Children and Adolescents With CKD: An International Delphi Survey. American Journal of Kidney Diseases, 2020, 76, 533-545.	1.9	19
20	Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?. Kidney International, 2020, 97, 1104-1106.	5.2	4
21	Prevalence of Cardiovascular Disease Risk Factors in Childhood Glomerular Diseases. Journal of the American Heart Association, 2019, 8, e012143.	3.7	22
22	Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN). Kidney International Reports, 2019, 4, 1725-1734.	0.8	13
23	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	5.2	38
24	Alport Syndrome and Other Collagen Disorders. , 2019, , 193-214.		0
25	Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatric Nephrology, 2019, 34, 261-267.	1.7	29
26	Kidney transplant outcomes associated with the use of increased risk donors in children. American Journal of Transplantation, 2019, 19, 1684-1692.	4.7	13
27	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. American Journal of Kidney Diseases, 2019, 73, 218-229.	1.9	68
28	The Social Media Revolution in Nephrology Education. Kidney International Reports, 2018, 3, 519-529.	0.8	88
29	Improved Outcomes of Kidney Transplantation in Infants (Age < 2 years). Transplantation, 2018, 102, 284-290.	1.0	17
30	Hearing loss and renal syndromes. Pediatric Nephrology, 2018, 33, 1671-1683.	1.7	12
31	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney International Reports, 2018, 3, 1373-1384.	0.8	39
32	Recurrence of nephrotic syndrome following kidney transplantation is associated with initial native kidney biopsy findings. Pediatric Nephrology, 2018, 33, 1773-1780.	1.7	32
33	Evolving Epidemiology of Pediatric Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 977-978.	4.5	10
34	Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. Nephrology Dialysis Transplantation, 2017, 32, gfw095.	0.7	40
35	The Evolution of the Journal Club: From Osler to Twitter. American Journal of Kidney Diseases, 2017, 69, 827-836.	1.9	126
36	Immunogenicity of Augmented Compared With Standard Dose Hepatitis B Vaccine in Pediatric Patients on Dialysis: a Midwest Pediatric Nephrology Consortium Study. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 772-778.	4.5	11

#	Article	IF	CITATIONS
37	Outcomes and Risk Factors for Graft Loss: Lessons Learned from 1,056 Pediatric Kidney Transplants at the University of Minnesota. Journal of the American College of Surgeons, 2017, 224, 473-486.	0.5	38
38	Infection rates in tacrolimus versus cyclosporineâ€treated pediatric kidney transplant recipients on a rapid discontinuation of prednisone protocol: 1â€year analysis. Pediatric Transplantation, 2017, 21, e12919.	1.0	14
39	Hemoglobin of 12 g/dl and above is not associatedÂwith increased cardiovascular morbidityÂin children on hemodialysis. Kidney International, 2017, 91, 177-182.	5.2	29
40	Alport Syndrome and Other Collagen Disorders. , 2017, , 1-22.		0
41	Nephrotic Syndrome: Updates and Approaches to Treatment. Current Treatment Options in Pediatrics, 2016, 2, 94-103.	0.6	5
42	The Genetics of Nephrotic Syndrome. Journal of Pediatric Genetics, 2016, 05, 015-024.	0.7	23
43	Inherited Glomerular Diseases. , 2016, , 777-803.		5
44	Alport Syndrome and Thin Basement Membrane Nephropathy. , 2016, , 499-514.		5
45	One-Year Mortality Rates in US Children with End-Stage Renal Disease. American Journal of Nephrology, 2015, 41, 121-128.	3.1	45
46	AKI in Children Hospitalized with Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2110-2118.	4.5	87
47	HLA-DQA1 and PLCG2 Are Candidate Risk Loci for Childhood-Onset Steroid-Sensitive Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2015, 26, 1701-1710.	6.1	118
48	Inherited Glomerular Diseases. , 2014, , 1-32.		0
49	Increasing frequency of acute kidney injury amongst children hospitalized with nephrotic syndrome. Pediatric Nephrology, 2014, 29, 139-147.	1.7	37
50	Nephrotic and Nephritic Syndrome in the Newborn. Clinics in Perinatology, 2014, 41, 605-618.	2.1	15
51	Renal and Urologic Abnormalities in the Perinatal Period. Clinics in Perinatology, 2014, 41, xix-xx.	2.1	2
52	Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium. Pediatric Nephrology, 2013, 28, 1235-1241.	1.7	22
53	Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatric Nephrology, 2013, 28, 5-11.	1.7	118
54	Antihypertensive pharmacotherapy and longâ€term outcomes in pediatric kidney transplantation. Clinical Transplantation, 2013, 27, 472-480.	1.6	22

#	Article	IF	CITATIONS
55	Rescue of tropomyosin deficiency in $\langle i \rangle$ Drosophila $\langle j \rangle$ and human cancer cells by synaptopodin reveals a role of tropomyosin $\hat{l}\pm$ in RhoA stabilization. EMBO Journal, 2012, 31, 1028-1040.	7.8	34
56	Graft loss due to recurrent disease in pediatric kidney transplant recipients on a rapid prednisone discontinuation protocol. Pediatric Transplantation, 2012, 16, 704-710.	1.0	9
57	Women and Alport syndrome. Pediatric Nephrology, 2012, 27, 41-46.	1.7	67
58	Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatric Blood and Cancer, 2011, 56, 674-676.	1.5	48
59	Kidney Function Reference Values in US Adolescents. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1956-1962.	4.5	25
60	Achieving racial parity in pediatric kidney transplantation: Yes we can. Pediatric Transplantation, 2010, 14, 807-808.	1.0	0
61	X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome. Nephrology Dialysis Transplantation, 2010, 25, 764-769.	0.7	51
62	Outcomes of infants <28Âdays old treated with peritoneal dialysis for end-stage renal disease. Pediatric Nephrology, 2009, 24, 2035-2039.	1.7	34
63	Distinct Target-Derived Signals Organize Formation, Maturation, and Maintenance of Motor Nerve Terminals. Cell, 2007, 129, 179-193.	28.9	215
64	Cat-scratch disease relapse in a kidney transplant recipient. Pediatric Transplantation, 2007, 11, 105-109.	1.0	22
65	Sarcoidosis presenting with hearing loss and granulomatous interstitial nephritis in an adolescent. Pediatric Nephrology, 2006, 21, 1323-1326.	1.7	16
66	Mouse Model of X-Linked Alport Syndrome. Journal of the American Society of Nephrology: JASN, 2004, 15, 1466-1474.	6.1	120